Lyell Immunopharma (LYEL) Cash from Operations (2020 - 2026)
Lyell Immunopharma (LYEL) reported Cash from Operations of 38510000.0 for Q1 2026, up 29.65% on a YoY basis from 29703807.18 in Q1 2025, and down 19.41% sequentially from 32251000.0 in Q4 2025.
Lyell Immunopharma (LYEL) Cash from Operations (2020 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 7 years of Cash from Operations data on file, last reported at 38510000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 29.65% year-over-year to 38510000.0; the trailing twelve-month figure through Mar 2026 stood at 133796000.0 (up 23.6% YoY), and the FY2025 full-year result was 150024000.0, up 7.62% from the prior year.
- Cash from Operations slipped to 38510000.0 in Q1 2026, from 32251000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 28577000.0 in Q3 2025 to a low of 54738000.0 in Q1 2025.
- A 5-year average of 40245705.88 and a median of 39161000.0 in 2023 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations tumbled 45.55% in 2022 and surged 31.73% in 2025, its largest moves.
- Tracing LYEL's Cash from Operations over 5 years: stood at 40267000.0 in 2022, then decreased by 0.91% to 40635000.0 in 2023, then retreated by 16.26% to 47242000.0 in 2024, then surged by 31.73% to 32251000.0 in 2025, then declined by 19.41% to 38510000.0 in 2026.
- Business Quant data shows LYEL's Cash from Operations at 38510000.0 in Q1 2026, 32251000.0 in Q4 2025, and 28577000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Lyell Immunopharma | 298.14 Mn | 298.14 Mn | - | -38.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.51 Mn |
| Mar 31, 2026 | -38.51 Mn |
| Dec 31, 2025 | -32.25 Mn |
| Dec 31, 2025 | -32.25 Mn |
| Sep 30, 2025 | -28.58 Mn |
| Sep 30, 2025 | -28.58 Mn |
| Jun 30, 2025 | -34.46 Mn |
| Jun 30, 2025 | -34.46 Mn |
| Mar 31, 2025 | -54.74 Mn |
| Mar 31, 2025 | -54.74 Mn |
| Dec 31, 2024 | -47.24 Mn |
| Dec 31, 2024 | -47.24 Mn |
| Sep 30, 2024 | -35.04 Mn |
| Sep 30, 2024 | -35.04 Mn |
| Jun 30, 2024 | -38.09 Mn |
| Jun 30, 2024 | -38.09 Mn |
| Mar 31, 2024 | -42.02 Mn |
| Mar 31, 2024 | -42.02 Mn |
| Dec 31, 2023 | -40.64 Mn |
| Dec 31, 2023 | -40.64 Mn |